Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2012

Mar 24, 2012

151_ip_2012-03-24_4f9b5883-ab02-4e47-9fc5-aa31e2586e0f.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Evotec AG , Full-Year Results 2011 , Frankfurt, 20th March 2012

Forward-looking s statements

Information set forth in this presen forward-looking statements, which invo risks and uncertainties ncertainties. The forward forward-lo contained herein represent the judgemen the date of this presentation. Such statements are neither promises nor gua subject to a variety of risks and uncert which are beyond our control control, and wh ntation containsolve a number ofoking statements nt of Evotec as offorward-looking arantees, but are tainties, many of hich couldcause

actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim an obligation or ndertaking to release p blicl any undertakingpublicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Welcome to Evoteec!

Your management team

Agenda

· Highlights 2011

  • Action Plan 2016 Innovation Efficiency
  • Operational & Financial Performance 2011
  • Growth Outlook

A very good year, with a strong outlook for 2012

Key themes & Highlights 2 2011

S
h
t
t
r
o
n
g
g
r
o
w		 f
4
%
l
i
h
€
8
8
0
2
0
4
%
i
i
b
i
l
i
h
€
2
5
t
t
t
t
t
t
t
t
5
o
p
n
e
g
r
o
o
m
o
p
e
r
a
n
g
p
r
o
a
g
r
o
o
m
w
y
w
•
-
,
,
f
4
4
%
i
€
1
0
i
i
i
h
l
t
t
g
r
o
s
s
m
a
r
g
n
m
p
o
s
e
o
p
e
r
a
n
g
c
a
s
o
;
v
w
S
f
d
b
k
d
i
l
i
i
i
d
i
t
t
t
t
t
r
o
n
g
o
r
e
r
o
o
a
n
m
e
s
o
n
e
o
p
p
o
r
n
e
s
n
c
a
e
r
e
e
n
e
s
o
u
v
u
•
€
8
8
€
9
0
i
2
0
1
2
m
m
n
–
P
i
l
i
i
t
h
t
p
e
n
e
w
o
u
t
e
x
p
o
s
u
r
e
o
f
i
i
l
i
k
n
a
n
c
a
r
s		 S
f
i
i
i
i
i
i
P
h
I
I
I
d
P
h
I
I
d
t
t
t
t
t
g
n
c
a
n
n
e
a
r-
e
r
m
o
p
p
o
o
r
n
e
s
n
a
s
e
a
n
a
s
e
p
r
o
c
u
u
•
d
l
h
i
t
t
e
v
e
o
p
m
e
n
p
a
r
n
e
r
s
p
s
s
f
B
d
l
i
l
i
0
5
t
t
t
r
o
a
o
n
g
e
r
m
p
p
e
n
e
o
o
a
r
g
e
s
•
-
~
M
k
t
a
r
e
l
i
d
i
t
c
o
n
s
o
a
o
n		 S
f
S
(
C
)
l
M
&
A
i
h
E
F
i
d
F
d
E
t
t
t
t
c
c
e
s
s
o
e
c
a
n
r
a
n
c
s
c
o
o
m
p
o
n
o
c
s
a
n
o
e
c
u
u
w
v
u
u
v
•
)
1
(
)
M
i
h
K
i
f
€
2
6
6
6
u
n
c
n
a
x
o
o
r
m
f
L
h
l
d
i
d
i
i
i
h
i
t
t
t
t
t
t
t
t
t
a
r
g
e
s
e
c
n
o
o
g
a
n
n
r
a
s
r
c
r
e
p
g
r
a
e
n
n
e
e
s
s
m
m
e
e
n
n
n
c
o
m
p
a
n
s
o
r
y
u
u
u
v
v
y
y
•
i
i
i
d
€
1
0
t
t
n
a
e
a
p
p
r
o
x
m
,
F
F
i
i
t
t
i
i
l
l
r
s
n
c
a
s
s
-
-
i
t
i
n
n
o
v
a
o
n		 F
F
d
d
i
i
i
i
h
i
i
i
h
h
l
l
i
i
i
i
d
d
i
i
h
d
t
t
t
t
t
t
o
c
s
e
n
e
s
m
e
n
s
n
g
n
n
o
a
e
s
c
o
e
r
r
e
s
e
a
r
c
a
r
e
a
s
a
n
u
v
y
v
v
v
y
•
d
i
l
l
i
€
8
4
a
c
a
e
m
c
a
a
n
c
e
s
a
p
p
r
o
o
x
m
,

Promised and delivered!

Completion of Action Plan 2012 (from 04/2009 - 03/2012)

A good starting point for further growth

Completion of Action Plan 2012 (from $04/2009 - 03/2012$ )

2) Acquisition of Zebrafish technology (UK); 5) Acquisition of Compound Focus (Evotec San Francisco) 3) Acquisition of Develogen (Evotec Goettingen)

Revenue guidance discovery alliance e was increased 2x following better e business and EVT 302 upfront

Overview financial guidan nce 2011

i
€
n
m
2
0
1
0		 1
)
2
0
1
1		 ∆ G
i
d
u
a
n
c
e
2
)
S
S
t
t
b
b
e
p
e
m
e
r		 G
i
d
u
a
n
c
e
M
M
h
h
a
r
c
R
e
v
e
n
u
e
s		 5
5		 8
0		 4
%
5
+		 9
7
7
7
-		 6
4
6
6
–
R
&
D
e
p
e
n
s
e
s
x		 6
1		 8
4		 3
8
%
+		 1
0
~		 1
0
~
O
i
i
t
p
e
r
a
n
g
n
c
o
m
e		 1
7		 2
5		 2
0
4
%
+		 I
d
m
p
r
o
e
o
e
r
v
v
2
0
1
0		 I
d
m
p
r
o
e
o
e
r
v
v
2
0
1
0
i
i
d
i
d
L
t
t
q
u
y
a
y
e
a
r
e
n		 7
0		 3
)
6
2		 6
0
>		 6
5
~
  • 7 1) 2011 incl. Kinaxo from April and incl. Compound Focus from June onwards
  • 2) Guidance adjusted with publication of partnering of EV VT 302 with Roche
  • 3) In 2011 a total of € 16.6m was spent in cash for acquisit ions incl. earn-out payments

Agenda

  • •Highlights 2011
  • • Action Plan 2016 – Innovation Efficiency
  • • Operational & Financial Performance 2011
  • •Growth Outlook

Dramatic decline in R&D productivity

Macro starting points – Er room´s law in Pharmaceutical R&D

Industry starts to a productivity throu appreciate increased gh external innovation

Customer starting points

Innovation efficienpharma and biotec ncy will be the driver for ch in the next decade

Action Plan 2016 - Forcesat work

Evo g as t e g o lving the glo Innovation Efficienoba eade l leader in ncy

Goals and controlling of A Action Plan 2016

Key Performance Indicators

G
r
o
w		 D
b
l
l
b
2
0
1
6
t
t
o
e
r
e
e
n
e
s
a
e
s
u
v
u
y
•
O
i
I
i
f
f
1
5
%
t
t
p
e
r
a
n
g
n
c
o
m
e
a
a
m
a
r
g
n
o
a
p
p
r
r
o
o
r
e
e
n
e
s
x
v
u
•
I
l
i
f
i
h
h
l
i
l
d
i
i
l
b
2
0
1
6
t
t
t
t
t
t
m
p
r
o
e
q
a
o
r
e
e
n
e
m
r
o
g
g
r
o
a
m
e
s
o
n
e
a
n
s
e
r
c
e
n
c
o
m
e
a
e
s
v
u
y
v
u
x
u
y
y,
v
y
•
I
t
n
n
o
v
a
e		 C
i
i
€
1
0
i
h
i
h
l
i
i
d
h
t
t
t
t
t
o
n
n
e
o
n
e
s
a
a
p
p
p
p
r
r
o
o
m
p
p
a
a
a
n
g
n
n
o
a
e
n
p
a
r
n
e
r
e
r
e
s
e
a
r
c
u
v
x
x
y
v
v
u
•
(
f
)
d
l
l
l
l
l
i
l
l
l
d
i
t
e
g
e
x
p
a
n
r
o
m
s
m
a
m
o
e
c
u
e
s
a
s
s
o
n
o
a
r
g
e
m
o
e
c
u
e
s
c
o
v
e
r
y
C
i
d
h
l
i
f
b
€
1
0
t
t
t
t
t
o
n
n
e
o
p
g
r
a
e
e
c
n
o
o
g
n
r
a
s
r
c
r
e
s
a
p
p
r
o
m
p
a
u
u
y
u
u
y
x
•
f
f
B
B
i
i
l
l
d
d
i
i
l
l
i
i
i
i
h
h
i
i
i
i
l
l
i
i
k
k
h
h
h
h
h
i
h
l
l
l
i
i
i
i
t
t
t
t
t
t
t
t
t
t
t
t
u
e
v
e
n
m
o
r
e
m
a
u
r
e
p
p
e
n
e
w
o
u
n
a
n
c
a
r
s
r
o
u
g
g
y
s
e
e
c
v
e
p
a
r
n
e
r
n
g
•
C
&
t
r
e
a
e
C
l
i
d
t
o
n
s
o
a
e		 A
i
l
i
i
i
i
k
l
i
d
i
t
t
t
t
t
t
t
c
e
p
a
r
c
p
a
e
n
s
r
a
e
g
c
m
a
r
e
e
c
o
n
s
o
a
o
n
v
y
•
O
i
i
h
h
l
d
l
i
t
t
p
m
s
e
s
a
r
e
o
e
r
a
e
c
r
e
a
o
n
v
u
•

Leveraging innovation efficient discovery

Action Plan 2016 - Evotec's offering for Innovation Efficiency

Broad stand alonee execution business

Comprehensive Drug Disc covery Platform – "EVO Apps"

Disease biology is the processor for integrated drug discovery alliances

Alliance model

"Faster to Decisioimproves innovati ns" business model on efficiency

Business model

Combining g leading platforms with wo gg y dru discovery rld class science

Accelerating process for fi rst-in-class innovation

F
o
c
s
u		 I
t
t
n
e
g
r
a
e		 E
i
n
g
n
e
e
e
r		 S
c
r
e
e
n
d
i
s
e
a
s
e
f
d
i
i
m
o
y
n
g
h
i
m
e
c
a
n
s
m
s		 i
e
m
e
r
g
n
g
i
i
h
t
i
n
s
g
s
n
d
i
b
i
l
s
e
a
s
e
o
o
g
y		 d
l
i
t
h
m
o
e
s
s
w
h
i
h
g
e
r
d
i
t
b
i
l
i
t
p
r
e
c
a
a
y		 t
t
i
l
l
s
s
e
m
a
c
a
y
y
,
&
b
i
d
u
n
a
s
e
h
i
c
o
m
p
r
e
e
n
s
v
e
C
f
l
b
i
t
t
e
a
r
e
n
e
o
•
i
t
t
p
a
e
n
s
O
O
b
b
i
i
o
s
v
u
•
d
i
f
f
i
i
t
t
t
e
r
e
n
a
o
n
o
i
i
h
i
t
t
e
x
s
n
g
e
r
a
p
e
s
T
b
l
i
d
t
r
a
c
a
e
n
r
g
u
•
d
i
s
c
o
e
r
p
r
o
c
e
s
s
v
y		 A
l
i
i
h
k
t
g
n
w
e
y
•
i
i
l
d
i
o
p
n
o
n
e
a
e
r
s
n
d
i
a
c
a
e
m
a
E
b
l
i
h
t
s
a
s
n
e
w
•
l
l
b
i
t
c
o
a
o
r
a
o
n
d
l
m
o
e
s
A
i
c
q
r
e
u
•
i
i
l
t
t
n
n
o
a
e
o
o
s
v
v
d
d
t
a
a
n
n
a
s
s
e
s		 R
l
t
e
e
v
a
n
c
e
o
•
h
d
i
u
m
a
n
s
s
e
a
s
e
P
P
i
i
i
i
t
t
r
o
m
o
x
y
•
d
i
i
f
i
s
e
a
s
e
s
s
p
e
c
c
h
i
m
e
c
a
n
s
s
m
C
b
i
H
C
o
m
n
e
•
d
i
h
t
t
r
e
a
o
s
u
w
h
h
t
t
r
o
g
p
u
u
u		 L
e
v
e
r
a
g
e
•
d
i
d
l
s
e
a
s
e
m
o
e
s
f
d
t
t
o
r
a
r
g
e
s
a
n
d
c
o
m
p
o
n
s
u
A
i
d
b
i
d
v
o
a
s
e
•
h
a
p
p
r
o
a
c
e
s
C
h
i
o
m
p
r
e
e
n
s
e
v
•
d
t
t
a
a
s
e
s
i
d
i
i
m
p
r
o
e
e
c
s
o
n
v
k
i
m
a
n
g		 A
l
d
i
t
i
r
e
a
e
s
n
g
y
x
i
i
t
i
t
i
n
a
v
e
s
:
C
B
t
r
e
e
a
u
C
C
N
N
h
h
r
e
e
p
r
o
n
u
f
P
t
t
i
l
t
o
e
n
a
u
u
r
e
i
i
t
i
t
i
n
a
v
e
s
C
P
i
u
r
e
a
n
C
N
r
e
e
r
o
n
u
u
C
I
f
l
i
t
u
r
e
n
a
m
m
a
o
n
C
H
t
u
r
e
e
a
r
…

Systematic, unbias mechanism-focusesed and comprehensive ed infrastructures

Accelerating first-in-class drug discovery innovation

H
i
h
g
l
l
i
i
t
t
r
e
s
o
o
n
u
i
e
x
p
r
e
s
s
o
n
l
i
a
n
a
y
s
s		 /
T
i
l
i
t
t
r
a
n
s
c
r
p
o
m
e
p
r
o
e
o
m
e
a
n
a
y
s
s
•
P
P
f
f
i
i
l
l
i
i
f
f
i
i
f
f
i
i
l
l
l
l
d
d
i
i
t
r
o
n
g
o
s
p
e
c
c
c
e
s
a
n
s
s
e
s
u
•
D
i
l
h
i
t
s
e
a
s
e
r
e
e
a
n
m
e
c
a
n
s
m
s
v
−
S
d
l
i
f
d
i
i
t
a
g
e
a
n
a
s
s
o
s
e
a
s
e
p
r
o
g
r
e
s
s
s
o
n
y
−
M
h
i
e
c
a
n
s
m
f
d
o
c
s
e
u
h
i
l
c
e
m
c
a
i
g
e
n
o
m
c
s		 S
h
i
i
d
h
i
h
l
l
l
t
t
t
t
o
p
s
c
a
e
g
c
o
n
e
n
c
e
u
a
r
a
s
s
s
a
y
•
P
i
l
l
/
i
t
r
m
a
r
y
c
e
s
s
s
u
e
s
−
I
l
i
d
l
l
t
m
m
o
r
a
s
e
c
e
s
−
f
H
i
h
i
t
t
g
c
o
n
e
n
s
c
r
e
e
n
n
g
o
•
A
d
l
i
b
i
t
t
n
n
o
a
e
r
a
r
e
s
−
D
i
l
i
b
i
v
e
r
s
e
r
a
r
e
s
−
N
N
l
l
d
d
t
t
t
t
a
r
a
p
r
o
c
s
u
u
−
M
h
i
e
c
a
n
s
m
f
d
o
c
u
s
e
f
i
l
t
n
c
o
n
a
u
i
t
p
r
o
e
o
m
c
s		 S
h
i
i
d
h
i
h
l
l
l
t
t
t
t
o
p
s
c
a
e
g
c
o
n
e
n
c
e
a
r
a
s
s
s
a
u
y
•
L
f
f
i
(
R
N
A
i
)
t
o
s
s
o
u
n
c
o
n
•
G
i
f
f
i
(
O
R
F
l
i
b
)
t
a
n
o
u
n
c
o
n
e
o
m
e
r
a
r
y
•
H
i
h
d
t
t
t
g
c
o
n
e
n
r
e
a
o
u
s
•

Deep product pipe eline without financial risk

Portfolio of product develo opment partnerships

Sig p nificant portfol assets without finaio of high-value ancial risk

Update on assets

E
V
T
3
0
2		 D
i
P
2
7
7
a
e
p
D
l
l
i
b
i
l
i
i
d
l
l
t,
t
t
t
e
v
e
o
p
m
e
n
r
e
g
u
a
o
r
y
r
e
s
p
o
n
s
e
s
a
n
a
c
o
s
s
•
h
b
f
d
R
h
t
t
a
v
e
e
e
n
r
a
n
s
e
r
r
e
o
o
c
e
f
D
l
i
l
i
l
l
d
l
t
t
t
t
t
t
e
v
e
o
p
m
e
n
p
r
o
e
c
a
n
p
o
e
n
a
y
a
r
g
e
s
a
n
a
o
n
e
•
l
i
i
b
i
i
t
t
t
t
t
a
p
p
c
a
o
n
o
r
c
o
m
n
a
o
n
r
e
a
m
e
n
s
L
P
h
I
I
b
i
l
i
i
f
i
2
0
1
2
t
t
t
t
a
r
g
e
a
s
e
r
a
n
p
r
e
p
a
r
a
o
n
o
r
s
a
r
n
•
P
h
I
I
b
l
i
d
P
h
I
I
I
d
/
2
0
1
3
2
0
1
4
t
t
t
a
s
e
c
o
m
p
e
o
n
a
n
a
s
e
s
a
r
e
n
•		 M
i
d
i
f
t P
h
I
I
I
i
l
(
B
l
l
f
i
)
1
t
t
s
t
t
t
e
p
r
m
a
r
y
e
n
p
o
n
o
a
s
e
r
a
e
a
c
e
u
n
c
o
n
;
•
)
1
d
d
i
i
f
i
i
f
C
i
d
l
l
t
t
t
t
t
e
m
o
n
s
r
a
e
a
s
g
n
c
a
n
p
r
e
s
e
r
v
a
o
n
o
-p
e
p
e
e
v
e
s
d
f
R
i
2
P
h
I
I
I
i
h
5
0
0
i
t
t
n
t
t
t
e
c
r
u
m
e
n
o
a
s
e
w
a
p
p
r
o
x.
p
a
e
n
s
•
d
b
l
d
b
i
d
2
0
1
2
t
t
t
e
x
p
e
c
e
o
e
c
o
m
p
e
e
y
m
t P
N
i
l
f
i
l
l
i
f
1
h
I
I
I
d
t
t
t
s
t
e
x
m
e
s
o
n
e
u
p
o
n
n
a
c
o
m
p
e
o
n
o
a
s
e
s
u
y
•
(
)
d
i
d
l
i
i
l
d
l
i
d
2
0
1
2
t
t
a
n
c
o
n
n
u
e
c
n
c
a
e
v
e
o
p
m
e
n
m
;
d
/
(
(
)
)
F
i
l
d
f
2
P
h
I
I
I
i
2
0
1
4
2
0
1
f
i
l
t
5
t
n
n
a
a
a
o
a
s
e
n
e
r
s
s
a
e
s
;
•
f
/
(
)
j
d
2
0
1
2
0
1
6
t
5
p
r
o
e
c
e
o
r
e
E
V
T
1
0
1
/
1
0
3		 O
h
l
i
i
l
/
l
i
i
l
t
e
r
c
n
c
a
p
r
e
-c
n
c
a
p
r
o
g
r
a
m
m
e
s
C
l
d
l
i
l
d
f
i
d
i
d
i
l
i
d
f
t
t
t
t
o
m
p
e
e
m
u
p
e
o
s
e
n
n
g
s
u
e
s,
s
o
s
a
e
y
•
f
i
l
p
r
o
e		 E
V
T
C
l
i
i
l
P
h
I
I
b
d
f
C
h
i
i
2
0
1
t
t
t
n
c
a
a
s
e
s
a
r
e
x
p
e
c
e
o
r
n
a
n
•
–
i
i
i
f
U
S
2
0
1
2
t
t
t

Agenda

  • · Highlights 2011
  • Action Plan 2016 Innovation Efficiency
  • Operational & Financial Performance 2011
  • Growth Outlook

Strong growth and profitability and in d clear investment strategy drive nnovation

Key financials FY 2011: Co ondensed profit & loss statement (IFRS)

2
0
0
9
A
l
t
c
a
u		 2
0
1
0
A
l
t
c
a
u		 2
0
1
1
A
l
t
c
a
u		 %
s
v
A
l
1
0
t
c
a
u
R
e
v
e
n
u
e
s		 4
2
7		 3
5
5		 8
0
1		 %
4
5
+
G
i
r
o
s
s
m
a
r
g
n		 4
3
2
%		 4
4
1
%		 %
4
3
7
R
&
D
e
x
p
e
n
s
e
s
•		 2
0
9		 6
1		 8
4		 3
8
%
+		 S
t
i
r
o
n
g
o
r
g
a
n
c
S
G
&
A
e
p
e
n
s
e
s
x
•		 1
6
7		 1
6
0		 1
8
5		 1
%
-		 t
h
g
r
o
w
t
m
o
m
e
n
u
m
A
i
i
t
t
m
o
r
s
a
o
n
•		 0
5		 0
7		 1
7		 -
r
e
v
e
n
u
e
s
I
i
t
m
p
a
r
m
e
n
•		 1
8
2		 0
0		 2
1		 l
d
i
e
x
c
u
n
g
f
R
l
i
i
t
e
v
e
r
s
a
o
m
p
a
r
m
e
n
•		 (
) .
0
4		 0
0.		 (
(
)
)
1
1
5
5		 i
i
t
i
a
c
q
u
s
o
n
s
R
i
t
t
e
s
r
u
c
u
r
n
g
e
x
p
e
n
s
e
s
•		 4
8		 0
0		 0
0		 %
3
0
+
O
h
i
t
t
e
r
o
p
e
r
a
n
g
e
p
e
n
s
e
s
x
•		 (
)
0
1		 (
)
0
1		 3
3
O
i
i
(
l
)
t
p
e
r
a
n
g
n
c
o
m
e
o
s
s		 (
4
2
3
)		 1
7
+		 5
2
+		 2
0
4
%
+
N
t
i
(
l
)
e
n
c
o
m
e
o
s
s		 (
4
5
5
)		 3
0
+		 6
7
+		 1
2
3
%
+

Growth driven by upfront payments and milestones

Milestones & gross margin n

Significantly impro oved profitability

Operating and net result

Strongp g o erating c infrastructure upg cash flow invested in rade and strategic acquisitions

Cash development in 2011 1

Visit the Manfred EEigen Campus in Hamburg

Significant upgrading proc cesses at all sites

Sales representation (Boston, Tokyo) Operations & sales representation

1) Manfred Eigen (*1927), German biophysical chemist and work on a special measuring method of fast chemical react d one of the worldwide leading pioneers in biotechnology. In 1967, he won the Nobel Prize in Chemistry for his ions, which, until then, were considered to be immeasurable. He initiated the foundation of Evotec AG.

Clear investment ffocus and good cost control

Overview R&D spend & SG G&A

Acquired technolo balance sheetogies and research reflected on

Balance sheet overview

Revenue momentuum maintained in Q4

Q4 2011 results

Q
4
2
0
1
0
A
l
t
c
a
u		 Q
Q
4
2
0
1
1
A
A
l
t
c
a
u		 %
s
v
A
l
1
0
t
c
a
u
R
e
e
n
e
s
v
u		 1
6
4		 2
0
4		 2
4
%
+		 €
2
1
i
i
t
m
m
p
a
r
m
e
n
•
G
i
r
o
s
s
m
a
r
g
n		 4
4
%.
2		 3
3
3
0
0
0
0
%
%		 f
2
0
1
E
V
T
o
R
&
D
e
x
p
e
n
s
e
s
•		 1
9		 1
7		 1
5
%
-		 M
i
d
i
t
a
r
g
n
r
e
u
c
o
n
•
S
G
&
A
e
x
p
e
n
s
e
s
•		 4
4		 4
3		 2
%
-		 d
h
i
f
t
e
o
p
a
s
n
g
o
u
i
l
t
m
e
s
o
n
e
s
A
i
i
t
t
m
o
r
s
a
o
n
•		 0
4		 0
5		 f
f
D
i
t
e
r
e
n
r
e
v
e
n
u
e
•
I
i
t
m
p
a
r
m
e
n
•		 0
0		 2
1		 i
(
d
m
x
c
o
m
p
o
u
n
t
f
R
l
i
i
t
e
v
e
r
s
a
o
m
p
a
r
m
e
n
•		 0
0.		 0
0
0
0		 )
m
a
n
a
g
e
m
e
n
I
i
h
t
n
c
r
e
a
s
e
n
o
e
r
•
R
i
t
t
e
s
r
u
c
u
r
n
g
e
x
p
e
n
s
e
s
•		 0
0		 0
0		 t
i
o
p
e
r
a
n
g
O
h
i
t
t
e
r
o
p
e
r
a
n
g
e
p
e
n
s
e
s
x
•		 0
1
-		 1
9		 d
t
e
p
e
n
s
e
s
e
o
x
u
f
t
t
i
i
t
O
i
i
(
l
)
t
p
e
r
a
n
g
n
c
o
m
e
o
s
s		 0
7
+		 4
3
-		 o
n
e
m
m
e
e
c
o
s
s
o
-
f
M
d
E
i
a
n
r
e
g
e
n
N
i
(
l
)
t
e
n
c
o
m
e
o
s
s		 2
2
+		 2
5
-		 C
a
m
p
u
s

Double digit reven financial performa nue growth and further improved ance in 2012 ff

Guidance 2012: Double diigit growth, higher profitability, more innovation

Agenda

  • · Highlights 2011
  • Action Plan 2016 Innovation Efficiency
  • Operational & Financial Performance 2011
  • Growth Outlook

Go for 2012!

Shareholder structure, upc coming key events & initiatives 2012

Strong news flow to come

Outlook and next steps for r 2012 ff

Key milestones for 2012

1
  • • Double digit revenue gro owth 2012 – 2016
  • EVT Execute Expansion success of ex xisting alliances
  • • Significant long-term dea als with major pharma

2EVT Integrate

  • • At l t eas 2 i ifi t 2 significant new wi t t d t h l /di integrated technology/disease alliances
  • • Deliver significant and a accelerated preclinical/clinical milestones
  • • Show operational synerg gies of recent acquisitions
3 E
V
T		 I
t
n
n
o
a
e
v
  • • At least 1 strategic deal for early assets
  • • Even more ven innovation u psides (e g (e.g. Cure X, …)
  • • Phase III data in DiaPep development partnership p277 and Phase II b start within product ps

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax [email protected]

More from Evotec SE

Director's Dealing 2026
May 22
Major Shareholding Notification 2026
May 21
Major Shareholding Notification 2026
May 19
Major Shareholding Notification 2026
May 18
Capital/Financing Update 2026
May 12
Regulatory Filings 2026
May 7
Regulatory Filings 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Regulatory Filings 2026
May 5
View all filings →